The FDA has accepted the new drug application (NDA) for tirabrutinib (ONO-4059), a highly selective, irreversible, second-generation Bruton tyrosine kinase (BTK) inhibitor developed for the treatment ...
Avoid common mistakes in multiplexing protein secretion assays. Discover best practices to ensure accurate results.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results